PRTA

Prothena Corporation plc is a late-stage clinical biotechnology company focused on discovering, developing, and commercializing novel therapies for neurodegenerative and rare peripheral amyloid diseases. Headquartered in Dublin, Ireland, with U.S. operations in South San Francisco, California, the company leverages its expertise in protein dysregulation to address conditions with significant unmet medical needs. Prothena's pipeline includes birtamimab, a Phase 3 asset targeting AL amyloidosis, and prasinezumab, an anti-alpha-synuclein antibody for Parkinson's disease developed in collaboration with Roche. The company also advances programs targeting neurodegenerative diseases including Alzheimer's disease through its tau and other protein-targeting candidates. Founded in 2012 as a spinoff from Elan Pharmaceuticals, Prothena maintains strategic partnerships with major pharmaceutical companies including Bristol Myers Squibb and Roche, which provide funding and development support for select programs. The company employs approximately 180 people and operates with a capital-efficient model that combines proprietary research with collaborative partnerships. In recent developments, Prothena reported positive Phase 2 data for birtamimab in AL amyloidosis and continues enrollment in pivotal studies. The company focuses on first-in-class and best-in-class antibody therapeutics targeting misfolded proteins, positioning itself within the growing field of protein dysregulation therapeutics for serious diseases affecting the brain, peripheral nerves, and vital organs.